437383-99-8

Usage

Uses

Used in Pharmaceutical Research:
4-(PYRIDIN-3-YLOXY)BENZOIC ACID is used as a research compound for its potential anti-inflammatory and anti-cancer properties, making it a valuable asset in the development of new medications.
Used in Drug Development:
In the pharmaceutical industry, 4-(PYRIDIN-3-YLOXY)BENZOIC ACID is used as a key intermediate in the synthesis of drugs targeting specific receptors in the body, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
4-(PYRIDIN-3-YLOXY)BENZOIC ACID is employed as a building block in the creation of complex organic molecules, facilitating the synthesis of a variety of chemical compounds with diverse applications.

InChI:InChI=1/C12H9NO3/c14-12(15)9-3-5-10(6-4-9)16-11-2-1-7-13-8-11/h1-8H,(H,14,15)

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 626-60-8 3-Chloropyridine 
• 58835-79-3 4-(pyridin-3-yloxy)benzonitrile 
• 877874-61-8 methyl 4-(pyridin-3-yloxy)benzoate 
• 87626-41-3 4-(pyridin-3-yloxy)-benzaldehyde 

Downstream Products

• 1442120-94-6 N-(2-methoxyethyl)-4-methyl-2-({1-[4-(pyridin-3-yloxy)benzoyl]piperidin-4-yl}methyl)-2H-indazole-5-carboxamide 

Relevant academic research and scientific papers

Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways

Guided by bioisosterism and pharmacokinetic parameters, we designed and synthesized a series of novel benzamide derivatives. Preliminary in vitro studies indicated that compounds 10b and 10j show significant inhibitory bioactivity in HepG2 cells (IC50 values of 0.12 and 0.13?μM, respectively). Compounds 10b and 10j induced the expression of HIF-1α protein and downstream target gene p21, and upregulated the expression of cleaved caspase-3 to promote tumor cells apoptosis.

COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a patient, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

SUBSTITUTED CARBOXYLIC ACID DERIVATIVES

The invention provides novel substituted carboxylic acid derivatives that bind to receptor as ligands of human peroxisome proliferator-activated receptor (PPAR) to activate it and exhibit potent triglyceride-lowering action, cholesterol-lowering action an